Impact of removal and restriction of me-too medicines in a hospital drug formulary on in- and outpatient drug prescriptions: interrupted time series design with comparison group

Vázquez-Mourelle, Raquel; Carracedo-Martínez, Eduardo; Figueiras, Adolfo

doi:10.1186/s13012-019-0924-0

Implementation Science

Table 2 Results of controlled interrupted segmented regression of time series

From: Impact of removal and restriction of me-too medicines in a hospital drug formulary on in- and outpatient drug prescriptions: interrupted time series design with comparison group

	Pre-intervention trend		Post-intervention
	Pre-intervention trend		Immediate impact of the formulary change		Change in trend after the formulary change
	Coefficient	95% confidence interval	Coefficient	95% confidence interval	Coefficient	95% confidence interval
DDD/TID
Total low molecular weight heparins	− 0.00368	− 0.01652 to 0.00916	− 0.22475	− 0.84762 to 0.39812	0.03792	− 0.00526 to 0.08110
Enoxaparin^a	− 0.02868*	− 0.03783 to − 0.01953	0.83432*	0.40110 to 1.26754	0.06759*	0.03701 to 0.09817
Bemiparin^b	0.00739*	0.00165 to 0.01313	− 0.44664*	− 0.70761 to − 0.18567	− 0.02817*	− 0.04681 to − 0.00953
Tinzaparin^c	0.013880*	0.00651 to 0.02125	− 0.26654*	− 0.45942 to − 0.07366	− 0.00187	− 0.01381 to 0.01007
Dalteparin^b	− 0.00071*	− 0.00136 to − 0.00006	− 0.02773*	− 0.05092 to − 0.00454	0.00141	− 0.00012 to 0.00294
Nadroparin^d	0.00062*	0.00005 to 0.00119	0.00459	− 0.01871 to 0.02789	− 0.00043	− 0.00200 to 0.00114
DDD/100 stays and day
Total low molecular weight heparins	− 0.27284	− 0.91964 to 0.37396	14.51816	− 13.64694 to 42.68326	− 1.80935	− 3.80400 to 0.18530
Enoxaparin^a	− 0.40854	− 1.01540 to 0.19832	41.83919*	15.89330 to 67.78508	− 0.20613	− 2.10147 to 1.68921
Bemiparin^b	− 0.24035*	− 0.42506 to − 0.05564	− 8.06595*	− 15.39245 to − 0.73945	− 0.88081*	− 1.42010 to − 0.34152
Tinzaparin^c	0.51274*	0.33291 to 0.69257	− 12.50797*	− 16.85966 to − 8.15628	− 0.51714*	− 0.82116 to − 0.21312
Dalteparin^b	−0.06482*	− 0.09016 to − 0.03948	− 1.25262*	− 2.15101 to − 0.35423	0.04139	− 0.01988 to 0.10266
Nadroparin^d	− 0.00018	− 0.00098 to 0.00062	0.01117	− 0.02974 to 0.05208	0.00016	− 0.00268 to 0.00300
Outpatient expenditure per DDD
Total low molecular weight heparins	0.00517*	0.00395 to 0.00639	− 0.11977*	− 0.17028 to − 0.06926	− 0.00786*	− 0.01139 to − 0.00433

^aThis was the only one that remained as a non-restricted prescription low molecular weight heparin in the formulary after the intervention
^bAfter the intervention, this low molecular weight heparin was removed from the formulary
^cAfter the intervention, this low molecular weight heparin was restricted to situations where enoxaparin could not be used
^dThis low molecular weight heparin had already been removed from the formulary before the intervention
*p < 0.05

Back to article page

ISSN: 1748-5908

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com